1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
3. INTRODUCTION
3.1. Overview of Aging
3.2. Types of Aging
3.3. Causes of Aging
3.4 Mechanism of Action of Anti-aging drugs market
3.5 Age-related Diseases
3.6 Key Facts Associated with Aging
3.7 Future Perspectives of Anti-aging drugs
4. MARKET LANDSCAPE
4.1. Anti-aging Drugs: Overall Market Landscape
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Type of Aging
4.1.3. Analysis by Phase of Development and Type of Aging
4.1.4. Analysis by Type of Molecule
4.1.5. Analysis by Mechanism of Action
4.1.6. Analysis by Type of Developers
4.2. Anti-aging Drugs: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Location of Headquarters
4.2.3. Leading Developers by Number of Therapeutics
4.2.4. Regional Landscape of Developers
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Anti-aging Drugs: Company Competitiveness Analysis
5.4.1. Small Companies
5.4.2. Mid-sized and Large Companies
6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Anti-aging Drugs: Partnerships and Collaborations
6.2.1 Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Leading Players: Analysis by Number of Partnerships
6.2.5. Analysis by Type of Partner
6.2.6. Analysis by Type of Agreement
6.2.7. Analysis by Region
6.2.7.1. Intercontinental and Intracontinental Deals
6.2.7.2. International and Local Deals
7. FUNDING AND INVESTMENTS
7.1. Chapter Overview
7.2. Anti-aging Drugs: Funding and Investments
7.2.1. Analysis of Instances by Year
7.2.2. Analysis of Amount Invested by Year
7.2.3 Analysis of Instances by Type of Funding
7.2.4. Analysis of Amount Invested by Type of Funding
7.2.5. Analysis by Type of Investor
7.2.6. Analysis by Focus Area
7.2.7. Analysis of Amount Invested by Region
7.2.8. Analysis of Amount Invested by Country
7.2.9. Most Active Investors: Analysis by Number of Instances
7.2.10. Most Active Players: Analysis by Number of Instances
7.2.11. Most Active Players: Analysis by Amount Invested
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Anti-aging Drugs: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Patent Publication Year
8.3.3. Analysis of Granted Patents by Year
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Analysis by Emerging Focus Areas
8.3.8. Analysis by Patent Age
8.3.9. Leading Industry Players: Analysis by Number of Patents
8.3.10. Leading Non-Industry Players: Analysis by Number of Patents
8.3.11. Leading Individual Assignees: Analysis by Number of Patents
8.4. Anti-aging Drugs: Patent Benchmarking
8.4.1. Analysis by Patent Characteristics
8.5. Anti-aging Drugs: Patent Valuation
9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Anti-aging Drugs: Publication Analysis
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Type of Publication
9.3.3. Most Popular Journals: Analysis by Number of Publications
9.3.4. Most Popular Journals: Analysis by Impact Factor
9.3.5. Analysis by Most Popular Keywords
9.3.6. Most Popular Funding Institutes: Analysis by Number of Publications
9.3.7. Most Active Publisher: Analysis by Number of Publications
9.3.8. Most Popular Affiliation: Analysis by Number of Publications
9.3.9. Analysis by Geography
10. PORTER’S FIVE FORCES ANALYSIS
10.1. Chapter Overview
10.2. Methodology and Key Parameters
10.3. Porter’s Five Forces
10.3.1. Threat of New Entrants
10.3.2. Bargaining Power of End Users
10.3.3. Bargaining Power of Drug Developers
10.3.4. Threat of Substitute Products
10.3.5. Rivalry Among Existing Competitors
11. COMPANY PROFILES
11.1. AgelessRx
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.3. Recent Developments and Future Outlook
11.2. ANOVA Institute for Regenerative Medicine
11.2.1. Company Overview
11.2.2. Product Portfolio
11.2.3. Recent Developments and Future Outlook
11.3. Betterhumans
11.3.1. Company Overview
11.3.2. Product Portfolio
11.3.3. Recent Developments and Future Outlook
11.4. BioAge Labs
11.4.1. Company Overview
11.4.2. Product Portfolio
11.4.3. Recent Developments and Future Outlook
11.5. bioXcellerator
11.5.1. Company Overview
11.5.2. Product Portfolio
11.5.3. Recent Developments and Future Outlook
11.6. Cambrian Biopharma
11.6.1. Company Overview
11.6.2. Product Portfolio
11.6.3. Recent Developments and Future Outlook
11.7. Gero.ai
11.7.1. Company Overview
11.7.2. Product Portfolio
11.7.3. Recent Developments and Future Outlook
11.8. Mayo Clinic
11.8.1. Company Overview
11.8.2. Product Portfolio
11.8.3. Recent Developments and Future Outlook
11.9. Rejuvenate Bio
11.9.1. Company Overview
11.9.2. Product Portfolio
11.9.3. Recent Developments and Future Outlook
11.10. UT Health San Antonio
11.10.1. Company Overview
11.10.2. Product Portfolio
11.10.3. Recent Developments and Future Outlook
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Forecast Methodology and Key Assumptions
12.2. Global Anti-aging Drugs Market, 2022-2040
12.2.1. Anti-aging Drugs Market: Analysis by Type of Molecule
12.2.2. Anti-aging v Market: Analysis by Type of Aging
12.2.3. Anti-aging Drugs Market: Analysis by Geography
12.2.3.1. Anti-aging Drugs Market in North America, 2022-2040
12.2.3.2. Anti-aging Drugs Market in Europe, 2022-2040
12.2.3.3. Anti-aging Drugs Market in Asia Pacific, 2022-2040
12.2.3.4. Anti-aging Drugs Market in Rest of the World, 2022-2040
12.2.4. Anti-aging Drugs: Forecast of Individual Product Sales
12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues
12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues
12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues
12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues
12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues
12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues
12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues
12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Gero.ai
13.2.1 Company Snapshot
13.2.2. Interview Transcript: Co-founder and Chief Executive Officer
13.3. Betterhumans
13.3.1. Company Snapshot
13.3.2. Interview Transcript: President
13.4. CytoMed Therapeutics
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Chief Operating Officer
13.5. Cambrian Biopharma
13.5.1 Company Snapshot
13.5.2. Interview Transcript: Senior Director of Global Corporate Communications
13.6. Landmark Medical Centre
13.6.1 Company Snapshot
13.6.2. Interview Transcript: Director and Consultant Obstetrician and Gynaecologist
LIST OF FIGURES
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investment Analysis
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Publication Analysis
Figure 2.6 Executive Summary: Market Forecast
Figure 3.1 Types of Aging
Figure 3.2 Causes of Aging
Figure 3.3 Mechanism of Action of Anti-aging Drugs
Figure 3.4 Age-related Diseases
Figure 4.1 Anti-aging Drugs: Distribution by Phase of Development
Figure 4.2 Anti-aging Drugs: Distribution by Type of Aging
Figure 4.3 Anti-aging Drugs: Distribution by Phase of Development and Type of Aging
Figure 4.4 Anti-aging Drugs: Distribution by Type of Molecule
Figure 4.5 Anti-aging Drugs: Distribution by Mechanism of Action
Figure 4.6 Anti-aging Drugs Developers: Distribution by Type of Developers
Figure 4.7 Anti-aging Drugs Developers: Distribution by Year of Establishment
Figure 4.8 Anti-aging Therapeutics Developers: Distribution by Company Size and Location of Headquarters
Figure 4.9 Leading Developers: Distribution by Number of Therapeutics
Figure 4.10 Anti-aging Drugs Developers: Regional Landscape
Figure 5.1 Company Competitiveness Analysis: Small Companies
Figure 5.2 Company Competitiveness Analysis: Mid-sized and Large Companies
Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 6.4 Leading Players: Distribution by Number of Partnerships
Figure 6.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 6.6 Partnerships and Collaborations: Distribution by Type of Agreement
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 6.8 Partnerships and Collaborations: International and Local Deals
Figure 7.1 Funding and Investments: Distribution of Instances by Year
Figure 7.2 Funding and Investments: Distribution of Amount Invested by Year
Figure 7.3 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding
Figure 7.4 Funding and Investments: Distribution of Instances by Type of Funding
Figure 7.5 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 7.6 Funding and Investments: Distribution by Type of Investor
Figure 7.7 Funding and Investments: Distribution by Focus Area
Figure 7.8 Funding and Investments: Distribution of Amount Invested by Region
Figure 7.9 Funding and Investments: Distribution of Amount Invested by Country
Figure 7.10 Most Active Investors: Distribution by Number of Instances
Figure 7.11 Most Active Players: Distribution by Number of Instances
Figure 7.12 Most Active Players: Distribution by Amount Invested
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Distribution by Patent Publication Year
Figure 8.3 Patent Analysis: Distribution of Granted Patents by Year
Figure 8.4 Patent Analysis: Distribution by Geography
Figure 8.5 Patent Analysis: Distribution by CPC Symbols
Figure 8.6 Patent Analysis: Distribution by Type of Applicant
Figure 8.7 Patent Analysis: Emerging Focus Area
Figure 8.8 Patent Analysis: Distribution by Patent Age
Figure 8.9 Leading Industry Players: Distribution by Number of Patents
Figure 8.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 8.12 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 8.13 Anti-aging Drugs: Patent Valuation
Figure 9.1 Publication Analysis: Distribution by Year of Publication
Figure 9.2 Publication Analysis: Distribution by Type of Publication
Figure 9.3 Most Popular Journals: Distribution by Number of Publications
Figure 9.4 Most Popular Journals: Distribution by Impact Factor
Figure 9.5 Publication Analysis: Most Popular Keywords
Figure 9.6 Most Popular Funding Institutes: Distribution by Number of Publications
Figure 9.7 Most Active Publisher: Distribution by Number of Publications
Figure 9.8 Most Popular Affiliation: Distribution by Number of Publications
Figure 9.9 Publication Analysis: Distribution by Geography
Figure 10.1 Anti-aging Drugs: Porter’s Five Forces Analysis
Figure 12.1 Global Anti-aging Drugs Market, 2035-2040 (USD Million)
Figure 12.2 Anti-aging Drugs Market: Distribution by Type of Molecule, 2022 and 2040 (USD Million)
Figure 12.3 Anti-aging Drugs Market: Distribution by Type of Aging, 2022 and 2040 (USD Million)
Figure 12.4 Anti-aging Drugs Market: Distribution by Geography, 2022 and 2040 (USD Million)
Figure 12.5 Anti-aging Drugs Market in North America, 2022-2040 (USD Million)
Figure 12.6 Anti-aging Drugs Market in Europe, 2022-2040 (USD Million)
Figure 12.7 Anti-aging Drugs Market in Asia Pacific, 2022-2040 (USD Million)
Figure 12.8 Anti-aging Drugs Market in Rest of the World, 2022-2040 (USD Million)
Figure 12.9 bioXgel (PRP) (bioXcellerator): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.10 AR-100 (Rejenevie Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.11 BGE-117 (BioAge Labs): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.12 Dasatinib and Quercetin (TruDiagnostic): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.13 MYMD-1 (MyMD Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.14 TRIIM Treatment (Intervene Immune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.15 Rapamycin (AgelessRx): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.16 Sarconeos (BIO101) (Biophytis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
LIST OF TABLES
Table 4.1 List of Anti-aging Drugs
Table 4.2 List of Anti-aging Drugs Developers
Table 6.1 Anti-aging Drugs: List of Partnerships and Collaborations
Table 7.1 Anti-aging Drugs: List of Funding and Investments
Table 8.1 Anti-aging Drugs: List of Patents
Table 8.2 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 9.1 Anti-aging Drugs: List of Publications
Table 11.1 AgelessRx: Product Portfolio
Table 11.2 AgelessRx: Recent Developments and Future Outlook
Table 11.3 ANOVA Institute for Regenerative Medicine: Product Portfolio
Table 11.4 Betterhumans: Product Portfolio
Table 11.5 Betterhumans: Recent Developments and Future Outlook
Table 11.6 BioAge Labs: Product Portfolio
Table 11.7 BioAge Labs: Recent Developments and Future Outlook
Table 11.8 bioXcellerator: Product Portfolio
Table 11.9 Cambrian Biopharma: Product Portfolio
Table 11.10 Cambrian Biopharma: Recent Developments and Future Outlook
Table 11.11 Gero.ai: Product Portfolio
Table 11.12 Gero.ai: Recent Developments and Future Outlook
Table 11.13 Mayo Clinic: Product Portfolio
Table 11.14 Mayo Clinic: Recent Developments and Future Outlook
Table 11.15 Rejuvenate Bio: Product Portfolio
Table 11.16 Rejuvenate Bio: Recent Developments and Future Outlook
Table 11.17 UT Health San Antonio: Product Portfolio
Table 11.18 UT Health San Antonio: Recent Developments and Future Outlook
Table 14.1 Market Landscape: Distribution by Phase of Development
Table 14.2 Market Landscape: Distribution by Type of Aging
Table 14.3 Market Landscape: Distribution by Phase of Development and Type of Aging
Table 14.4 Market Landscape: Distribution by Type of Molecule
Table 14.5 Market Landscape: Distribution by Mechanism of Action
Table 14.6 Developer Landscape: Distribution by Type of Developers
Table 14.7 Developer Landscape: Distribution by Year of Establishment
Table 14.8 Developer Landscape: Distribution by Company Size and Location of Headquarters
Table 14.9 Leading Developers: Distribution by Number of Therapeutics
Table 14.10 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.11 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.12 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.13 Leading Players: Distribution by Number of Partnerships
Table 14.14 Partnerships and Collaborations: Distribution by Type of Partner
Table 14.15 Partnerships and Collaborations: Distribution by Type of Agreement
Table 14.16 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 14.17 Partnerships and Collaborations: International and Local Deals
Table 14.18 Funding and Investments: Distribution of Instances by Year
Table 14.19 Funding and Investments: Distribution of Amount Invested by Year
Table 14.20 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding
Table 14.21 Funding and Investments: Distribution of Instances by Type of Funding
Table 14.22 Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 14.23 Funding and Investments: Distribution by Type of Investor
Table 14.24 Funding and Investments: Distribution by Focus Area
Table 14.25 Funding and Investments: Distribution of Amount Invested by Region
Table 14.26 Funding and Investments: Distribution of Amount Invested by Country
Table 14.27 Most Active Investors: Distribution by Number of Instances
Table 14.28 Most Active Players: Distribution by Number of Instances
Table 14.29 Most Active Players: Distribution by Amount Invested
Table 14.30 Patent Analysis: Distribution by Type of Patent
Table 14.31 Patent Analysis: Distribution by Patent Publication Year
Table 14.32 Patent Analysis: Distribution of Granted Patents by Year
Table 14.33 Patent Analysis: Distribution by Geography
Table 14.34 Patent Analysis: Distribution by Type of Applicant
Table 14.35 Patent Analysis: Distribution by Patent Age
Table 14.36 Leading Industry Players: Distribution by Number of Patents
Table 14.37 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.38 Leading Individual Assignees: Distribution by Number of Patents
Table 14.39 Anti-aging Drugs: Patent Valuation
Table 14.40 Publication Analysis: Distribution by Year of Publication
Table 14.41 Publication Analysis: Distribution by Type of Publication
Table 14.42 Most Popular Journals: Distribution by Number of Publications
Table 14.43 Most Popular Journals: Distribution by Impact Factor
Table 14.44 Most Popular Funding Institutes: Distribution by Number of Publications
Table 14.45 Most Active Publisher: Distribution by Number of Publications
Table 14.46 Most Popular Affiliation: Distribution by Number of Publications
Table 14.47 Publication Analysis: Distribution by Geography
Table 14.48 Global Anti-aging Drugs Market, Conservative, Base and Optimistic Scenarios, 2035-2040 (USD Million)
Table 14.49 Anti-aging Drugs Market: Distribution by Type of Molecule, 2022 and 2040 (USD Million)
Table 14.50 Anti-aging Drugs Market: Distribution by Type of Aging, 2022 and 2040 (USD Million)
Table 14.51 Anti-aging Drugs Market: Distribution by Geography, 2022 and 2040 (USD Million)
Table 14.52 Anti-aging Drugs Market in North America, 2022-2040 (USD Million)
Table 14.53 Anti-aging Drugs Market in Europe, 2022-2040 (USD Million)
Table 14.54 Anti-aging Drugs Market in Asia Pacific, 2022-2040 (USD Million)
Table 14.55 Anti-aging Drugs Market in Rest of the World, 2022-2040 (USD Million)
Table 14.56 bioXgel (PRP) (bioXcellerator): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.57 AR-100 (Rejenevie Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.58 BGE-117 (BioAge Labs): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.59 Dasatinib and Quercetin (TruDiagnostic): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.60 MYMD-1 (MyMD Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.61 TRIIM Treatment (Intervene Immune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.62 Rapamycin (AgelessRx): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.63 Sarconeos (BIO101) (Biophytis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
